Elise T Zeiser
Overview
Explore the profile of Elise T Zeiser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mojica M, Nukaga M, Becka S, Zeiser E, Hoshino T, LiPuma J, et al.
ACS Infect Dis
. 2024 Oct;
10(11):3810-3820.
PMID: 39440926
In our curated panel of complex isolates, strain AU28442 was unusually highly β-lactam resistant. To explore the molecular mechanisms leading to this phenotype, we performed whole genome sequencing (WGS) and...
2.
Mojica M, Zeiser E, Becka S, Six D, Moeck G, Papp-Wallace K
Microbiol Spectr
. 2024 Sep;
12(11):e0114424.
PMID: 39315842
Taniborbactam (formerly VNRX-5133) is a novel, investigational boronic acid β-lactamase inhibitor. The combination of cefepime (FEP) with taniborbactam is active against carrying class A, B, C, and/or D enzymes. We...
3.
Mojica M, Zeiser E, Becka S, LiPuma J, Six D, Moeck G, et al.
Antimicrob Agents Chemother
. 2023 Sep;
67(11):e0049823.
PMID: 37768313
The novel clinical-stage β-lactam-β-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D β-lactamases. We tested this combination against a panel of...
4.
Papp-Wallace K, Barnes M, Taracila M, Bethel C, Rutter J, Zeiser E, et al.
Antibiotics (Basel)
. 2023 May;
12(5).
PMID: 37237794
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying . However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer...
5.
Zeiser E, Becka S, LiPuma J, Papp-Wallace K
Antimicrob Agents Chemother
. 2022 Dec;
67(1):e0135222.
PMID: 36507667
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity...
6.
Becka S, Zeiser E, LiPuma J, Papp-Wallace K
Antibiotics (Basel)
. 2022 May;
11(5).
PMID: 35625319
Tebipenem-pivoxil hydrobromide, an orally bioavailable carbapenem, is currently in clinical development for the treatment of extended-spectrum β-lactamase- and AmpC-producing Enterobacterales. Previously, tebipenem was found to possess antimicrobial activity against the...
7.
Becka S, Zeiser E, LiPuma J, Papp-Wallace K
Antimicrob Agents Chemother
. 2021 Aug;
65(11):e0133221.
PMID: 34370574
The Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic pathogens that most commonly infect persons with cystic fibrosis or compromised immune systems. Members of the genus are intrinsically multidrug...
8.
Nukaga M, Yoon M, Taracilia M, Hoshino T, Becka S, Zeiser E, et al.
ACS Infect Dis
. 2021 Mar;
7(4):826-837.
PMID: 33723985
complex (Bcc) poses a serious health threat to people with cystic fibrosis or compromised immune systems. Infections often arise from Bcc strains, which are highly resistant to many classes of...
9.
Papp-Wallace K, Shapiro A, Becka S, Zeiser E, LiPuma J, Lane D, et al.
Antimicrob Agents Chemother
. 2020 Dec;
65(3).
PMID: 33318017
The Gram-negative bacterial genus includes several hard-to-treat human pathogens: two biothreat species, (causing glanders) and (causing melioidosis), and the complex (BCC) and , which cause chronic lung infections in persons...
10.
Papp-Wallace K, Kumar V, Zeiser E, Becka S, van den Akker F
Antibiotics (Basel)
. 2019 Sep;
8(3).
PMID: 31514291
Carbapenem-resistant Enterobacteriaceae are a significant threat to public health, and a major resistance determinant that promotes this phenotype is the production of the OXA-48 carbapenemase. The activity of OXA-48 towards...